Prophylactic prednisolone for the prevention of early and intermediate adverse effects of radioactive iodine therapy in patients with thyroid cancer: study protocol for a single-centre, phase II/III, randomized, double-blinded, placebo-controlled clinical trial

BACKGROUND: Radioactive iodine (RAI) therapy is the standard adjuvant treatment for differentiated thyroid cancer (i.e. papillary and follicular). RAI is associated with troublesome early, intermediate and late adverse effects. Although glucocorticoids are used for the management of these adverse ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Jayarajah, Umesh, Wijekoon, Mahilal, Seneviratne, Sanjeewa A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526358/
https://www.ncbi.nlm.nih.gov/pubmed/32993815
http://dx.doi.org/10.1186/s13063-020-04744-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526358/
https://www.ncbi.nlm.nih.gov/pubmed/32993815
http://dx.doi.org/10.1186/s13063-020-04744-x

Ejemplares similares